Action Members are any researcher who participates actively in PROTEOSTASIS. All Members belong to one or more Working Group. Members can include researchers from COST Countries, Near Neighbour and International Partner Countries.
 |
Petek Ballar Please log-in to see email and phone. |
Ege University http://www.ege.edu.tr Turkey |
WG4 |
| Ubiquitin mediated proteasomal degradation, Endoplasmic Reticulum associated degradation | |||
 |
Pétur Henry Petersen Please log-in to see email and phone. |
University of Iceland http://lifvisindi.hi.is Iceland |
WG6 |
| Speciality: Cell biology of Neurodegenerative diseases. Skills: Work on model organisms Drosophila and the mouse. Gene expression analysis, protein studies. Cell culture. | |||
 |
Philippe Soubeyran Please log-in to see email and phone. |
INSERM U168. CRCM. Parc Scientifique de Luminy http://crcm.marseille.inserm.fr France |
WG1 |
| Our previous work focused on the study of the role of ArgBP2, a multi-adapter protein, in pancreatic cancer. At present, our goal is to generate the Ubiquitin and Ubiquitin-like specific proteomes of pancreatic cancer cells, and to identify changes induced by anticancer treatments which could be responsible for the exacerbated resistance of this type of cancer cells to any form of therapy. The next steps will be to validate the importance of these altered post-translational modifications regarding the resistance of pancreatic cancer cells to treatments and then to find a way to block them to increase the efficacy of current treatments. | |||
 |
Pierre G Lutz Please log-in to see email and phone. |
CNRS (centre National de la Recherche Scientifique)/ Institute of Pharmacology and Structural Biology, UMR5089 CNRS / UPS http://www.ipbs.fr France |
WG6 |
| Mouse models (knockout mice, embryonic and adult mouse hematopoiesis, transplantation, ); Cell biology (differentiation, flow cytometry, quantitative immunofluorescence microscopy, characterization of hematopoietic stem and progenitor cells); Biochemistry, mass spectrometry and molecular biology, Ubiquitin and ubiquitin-like. | |||
 |
Pierre Goloubinoff Please log-in to see email and phone. |
University of Lausanne http://www.unil.ch Switzerland |
WG3 |
| Recombinant DNA technology and methods of protein design, expression and purification. Our major expertize is to perform a great variety of in vitro chaperone activity assays. We have developed various chaperone substrates (inactive unfolded, misfolded monomers, soluble aggregates, protofibrilar and fibrillar aggregates, alternatively folded and assembled protein complexes) to characterize different chaperone activities. We are also experts of the heat-shock response in plants and animals and of Calcium channel mediated-heat-sensing in eukaryotes. | |||
 |
Pitter F. Huesgen Please log-in to see email and phone. |
Central Institute for Engineering, Electronics and Analytics, (ZEA-3), Forschungszentrum Jülich http://www.proteasedegradomics.org Germany |
WG3 |
| Proteomics, proteases, biochemistry, plant sciences, mass spectrometry imaging | |||
 |
Ralf Braun Please log-in to see email and phone. |
Universität Bayreuth http://www.zellbiologie.uni-bayreuth.de Germany |
|
| Neurodegeneration is characterized by the disease-specific loss of neuronal activity, culminating in the irreversible destruction of neurons. Neuronal cell death can proceed via distinct subroutines such as apoptosis and necrosis, but the underlying molecular mechanisms remain poorly understood. Saccharomyces cerevisiae is an established model for programmed cell death, characterized by distinct cell death pathways conserved from yeast to mammals. We are using yeast models for several neurodegenerative disorders, including Alzheimer disease, and motor neuron diseases. Heterologous expression of human proteins implicated in these disorders triggers growth deficits, loss of clonogenic survival, induction of oxidative stress, apoptosis and necrosis in yeast. We aim at the mechanistic dissection of the underlying cell death pathways in yeast, with especial focus on proteolytic pathways (ubiquitin-proteasome system, UPS, and the autophagy-lysosomal pathway, ALP), and their interconnections with mitochondrial health. We trust that the mechanisms described in yeast will enable the targeted validation in higher model organisms, and will therefore contribute to a better understanding of human neurodegenerative disorders. | |||
 |
Ralf Stohwasser Please log-in to see email and phone. |
Brandenburg Technical University (BTU) Cottbus-Senftenberg http://www.b-tu.de Germany |
WG2 |
| Proteolytic pathways in apoptosis and autophagy, ubiquitin proteasome system, PA28 regulators of proteasomes, tumor biology, cell models | |||
 |
rappoteur Please log-in to see email and phone. |
No website |
|
 |
Rasmus Hartmann-Petersen Please log-in to see email and phone. |
University of Copenhagen http://www1.bio.ku.dk Denmark |
WG4 |
| ubiquitin-binding proteins, degradation of misfolded proteins, proteasome-associated proteins | |||
 |
[email protected] Please log-in to see email and phone. |
Aarhus University http://www.sureshrattan.com Denmark |
WG2 |
| Ageing, aging, healthy ageing, stress, hormesis, protein synthesis, protein modifications, protein turnover, lysosome, autophagy, proteasome. Unravelling the cellular and molecular basis of ageing, specially at the level of protein synthesis, modifications, turnover, and stress responses | |||
 |
Regina Menezes Please log-in to see email and phone. |
Institute of Experimental Biology and Technology (iBET) http://www.itqb.unl.pt Portugal |
WG6 |
| Polyphenols bioaccessability and bioavailability (in vitro digestion, human intervention studies and brain permeability). In particular study of the molecular mechanisms affected by plant phenolic compounds on inflammation, cancer, hematological and neurodegenerative diseases by using humanized yeast and mammalian cell models (including neuroinflammation, neurodegenaration, blood brain barrier integrity and Parkinson disease cell models). | |||
 |
Rens Voesenek Please log-in to see email and phone. |
Institute of Environmental Biology http://www.uu.nl Netherlands |
WG3 |
| Mechanistic studies on how plants deal with flooding stress en changes in their light environment. | |||
 |
Reuven Wiener Please log-in to see email and phone. |
Hebrew University http://medicine.ekmd.huji.ac.il Israel |
WG1 |
| Structure-function studies of the ubiquitin system. | |||
 |
Ricardo Escalante Please log-in to see email and phone. |
Instituto de Investigaciones Biomédicas Alberto Sols. IBB. CSIC http://www2.iib.uam.es Spain |
WG2 |
| We are studying the molecular mechanisms of autophagy in Dictyostelium and human cell lines and the potential impact of new proteins in autophagy-related pathologies. | |||
 |
Robert Layfield Please log-in to see email and phone. |
Molecular Cell Science Group. University of Nottingham http://www.nottingham.ac.uk United Kingdom |
WG6 |
| - dysfunction of ubiquitin-mediated processes (including autophagy) in: Paget's disease of bone; skeletal muscle atrophy; neurodegenerative disorders - defining the complexity of (poly)ubiquitin modifications in vivo - mechanisms of ubiquitin recognition - the application of proteomics-based methods to the above | |||
 |
Robert Sarisky Please log-in to see email and phone. |
FORMA Therapeutics http://www.formatherapeutics.com USA |
WG1 |
| Deubiquitination, Sumoylation, E-ligases, and Epigenetic readers/writers / erasers and super-enhancers. | |||
 |
Robert Weil Please log-in to see email and phone. |
Institute Pasteur http://webcampus.pasteur.fr France |
WG3 |
| The first axis of our research is to understand the molecular mechanism of Nuclear factor-?B (NF-?B) activation following TCR-stimulation. We also address fundamental question concerning the general mechanism of NF-?B activation such as understanding how specific type of ubiquitin chains enables inflammatory and immunity-inducing signalling events. Emmanuel Laplantine (CR1, CNRS) developed this project. The second axis of our research concerns the function of the protein Optineurin (Optn). Our ongoing studies of the NF-?B pathway led in parallel to the identification and characterization of Optn, an apparent paralog of NEMO, the central regulator of NF-?B. Optn is an extremely versatile protein that is a key player in host defense against pathogens. Optn gene has been linked to diverse pathological processes such as open angle glaucoma, amyotrophic lateral sclerosis and Paget?s disease of bone. An important contribution of my team has been the discovery of a novel function of Optn in the regulation of mitosis and our future projects are to investigate the molecular mechanisms responsible for the mitotic function of Optn and to establish how Optn coordinate host defense mechanisms during mitosis. We also address fundamental question concerning the role of ubiquitin in antiviral innate immunity. Pierre G | |||
 |
Rodolfo Negri Please log-in to see email and phone. |
Dipartimento di Biologia e Biotecnologie. Sapienza Università di Roma http://bbcd.bio.uniroma1.it Italy |
WG2 |
| Speciality: yeast functional genomics and epigenomics. Skills: Yeast genetics and cellular biology, Transcriptomics and transcriptional regulation analysis, Chromatin immunoprecipitation, proteomics, fluorescent and confocal microscopy. | |||
 |
Ronald T Hay Please log-in to see email and phone. |
Wellcome Trust Centre for Gene Regulation and Expression. College of Life Sciences. University of Dundee http://www.lifesci.dundee.ac.uk United Kingdom |
WG3 |
| Establishing the role of SUMO modification in the response of cells to DNA damage. Determining the structure and function of the SUMO targeted ubiquitin E3 ligase RNF4. Defining the pathway that leads to degradation of the Promyelocytic Leukaemia protein during arsenic therapy for Acute promyelocytic Leukaemia Investigating the role of SUMO modification in response to proteotoxic stress. | |||
 |
Rosa Barrio Please log-in to see email and phone. |
CIC bioGUNE http://personal.cicbiogune.es Spain |
WG3 |
| We investigate biomedically relevant genes and processes using Drosophila melanogaster and mouse as model systems, as well as human cells. We are interested on the role of SUMOylation in development, steroidogenesis, ciliogenesis and growth, through the modification of transcription factors. | |||
 |
Rosa Farràs Rivera Please log-in to see email and phone. |
Centro de Investigación Principe Felipe CIPF http://www.cipf.es Spain |
WG6 |
| A major focus of our work is to understand the regulatory mechanisms of protein turnover of cell cycle-related proteins and how these processes impact on proliferation, differentiation and tumorigenesis. This is a critical area of cancer research, since accelerated cell growth and deregulated protein turnover is a major feature of tumour formation and progression. In addition, cellular differentiation is also associated with the regulation of protein turnover and often antagonises carcinogenesis. We believe that a better understanding of the molecular basis of malignant transformation will lead not only to further advances in cancer biology but also to help develop novel and effective cancer therapies. | |||
 |
Rudi Beyaert Please log-in to see email and phone. |
VIB and Ghent University http://www.vib.be Belgium |
WG3 |
| With our research we want to contribute to the understanding of molecular signaling mechanisms that control inflammation and immunity. Our current activities are focused mainly on the nuclear factor-kB (NF-kB) signaling pathway, which is activated in response to injury, infection, inflammation and other stressful conditions requiring rapid reprogramming of gene expression. Inappropriate NF-kB dependent gene expression is implicated in the pathogenesis of inflammatory diseases and cancer. We are using several molecular and biochemical approaches to generate fundamental knowledge on signaling mechanisms that control and fine-tune NF-kB activation downstream of specific receptors involved in inflammation and immunity (TNF-R, IL-33R, TLRs, RLRs, TCR). We are also studying a number of other signaling pathways that sometimes crosstalk with NF-kB signaling, such as interferon regulatory factor (IRF) signaling and autophagy. A common theme in our research is the role of ubiquitin-mediated signaling. | |||
 |
ruhr university bochum Please log-in to see email and phone. |
No website |
|
 |
Rui Vitorino Please log-in to see email and phone. |
University of Aveiro http://www.ua.pt Portugal |
WG6 |
| Development and application of proteomics approaches to the analysis of proteins and peptides from tissues and body fluids, which could disclose modified molecular pathways and potential targets for diseases diagnostic, therapeutic and prognostic, and novel therapeutic approaches. To do this, my research plan is focused on saliva proteomics and peptidomics and relies on three main goals: i) characterization of salivary proteins using magnetic nano-probe platforms; ii) identification of bioactive peptides based on peptidomics; iii) clinical proteomics. | |||
 |
Rune Matthiesen Please log-in to see email and phone. |
IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto http://www.ipatimup.pt Portugal |
WG1 |
| MS based drug profiling or pharmacoproteomics with the aim of obtaining mechanistic insight into drug function | |||
 |
Sanjeev Gupta Please log-in to see email and phone. |
NATIONAL UNIVERSITY OF IRELAND GALWAY No website Ireland |
WG6 |
| The main focus of research in my group is to evaluate the role of microRNAs in determining cell fate during conditions of ER stress. We use a combination of molecular cell biology, transcriptomics, proteomics and miRNA expression profiling to address specific questions such as: (i) What is the role of miRNAs in ER stress-induced apoptosis? (ii) Does impaired miRNA biogenesis contribute to cancer progression by inhibiting ER stress-induced apoptosis? The second line of work in my group is to elucidate the role of IRE1-XBP1 axis in endocrine resistance in ER-positive breast cancer. We are taking a multidisciplinary approach to elucidate the role of the IRE1-XBP1 in regulation of estrogen signalling underpinning anti-estrogen resistance in breast cancer. | |||
 |
Sara Sigismund Please log-in to see email and phone. |
IFOM. Fondazione Istituto FIRC di Oncologia Molecolare No website Italy |
WG3 |
| A long-standing goal of our group is to elucidate the role of ubiquitination in the regulation of EGFR endocytosis and intracellular signaling. Currently, our ongoing projects are aimed at elucidating the molecular mechanisms governing ubiquitination and endocytosis of the EGFR, mapping the endocytic interactome and understanding the functional significance of EGFR ubiquitination and endocytosis in normal physiological processes and in disease, particularly in cancer | |||
 |
Sarit Larisch Please log-in to see email and phone. |
University of Haifa, Israel http://www.wix.com Israel |
WG2 |
| Speciality: My lab focuses on investigating signaling pathways of cell death (apoptosis) and cancer. In particular, we are concentrating on proteins that are regulated via the Ubiquitin-Proteasome System (UPS). Specifically, we investigate the mechanism by which pro-apoptotic proteins promote apoptosis through UPS-mediated degradation of apoptotic inhibitors (including IAPs - Inhibitor of Apoptosis proteins, and Bcl-2). We discovered mutual regulation interactions by which these proteins regulate cell death through UPS-mediated protein degradation. Moreover, we found that a key pro-apoptotic protein that we identified, termed ARTS, functions as a powerful tumor suppressor protein, and that its expression is lost in many types of cancers. Overexpression of anti-apoptotic IAPs (in particular XIAP) and Bcl-2 are characteristics of many types of cancers. One of our current goals is to develop small molecules which induce UPS-mediated degradation of these anti-apoptotic proteins, serving as IAP-antagonists and Bcl-2 antagonists for cancer therapy. Skills:Cellular and molecular Biology. Cancer Biology, Biochemistry and fluorescence microscopy. Ubiquitination assays. In general, my lab works on investigating signaling pathways, apoptosis, cancer and invasion of cancer cells, protein-protein interactions, and developing peptides and small molecules for killing cancer cells (as anti-cancer therapeutics). | |||